Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
Elevai Labs, Inc. (NASDAQ: ELAB) is a California-based medical aesthetics company that specializes in physician-dispensed skincare products. Elevai leverages cutting-edge science-driven technologies to modernize the aesthetic skincare market. The company has commercialized its proprietary ELEVAI Exosomes, a next-generation, patent-pending technology used in its flagship skincare products.
Recently, Elevai launched an online e-commerce portal, expanding their business-to-business (B2B) relationships to retail customers. This platform allows customers to select a physician provider to start their personalized skincare journey and enjoy the convenience of online re-ordering. The launch supports Elevai’s sales and marketing initiatives, reflecting the company's commitment to providing a medically-guided customer experience.
Elevai also announced unaudited 113% year-over-year (YoY) Q4 sales growth and 75% YoY Q4 new account growth. The company's robust infrastructure enables the quick launch of new products utilizing the same ELEVAI exosome platform technology.
In terms of global expansion, Elevai recently signed an exclusive distribution agreement with ILIA International Ltd. in Taiwan. This partnership is set to distribute ELEVAI’s patented skincare products, leveraging ILIA’s expertise and access to Taiwan's high-end medical aesthetics market. Elevai has secured a total of five international distribution agreements with a cumulative minimum purchase requirement commitment of up to $4.9 million over the next five years.
Elevai Biosciences, a division of the company, is focusing on the development of aesthetic medicines. One of its lead assets, EL-22, is an engineered probiotic aimed at treating obesity by preserving muscle mass while decreasing fat mass. Preclinical studies suggest that EL-22 has the potential to work in combination with GLP-1 receptor agonists like Ozempic and Mounjaro.
Elevai's commitment to innovation and collaboration positions it as a leader in the medical aesthetics industry. The company continues to empower physicians and enhance customer outcomes through its innovative skincare solutions.
Elevai Labs Inc. (NASDAQ: ELAB) has announced positive case study results for its E-Series exosome technology in potential melasma applications. The study, conducted by Dr. Chau Ngoc To Trinh in Vietnam, involved four female patients with moderate to severe mixed type melasma. A triple combination method was used, including Er:YAG and Nd:YAG lasers, followed by Elevai's topical exosome products.
Key findings include:
- Significant improvement after two months of treatment
- No melasma recurrence after six months
- Potential synergistic effects between laser therapy and exosome products
The global melasma treatment market is expected to grow from $2.85 billion in 2022 to $4.83 billion by 2030, with a CAGR of 6.8%. Elevai plans to conduct larger studies to further demonstrate the potential of combining their exosome products with laser therapy for melasma treatment.
Elevai Labs, Inc. (NASDAQ: ELAB) has announced promising results from an ongoing research study on hair restoration using their proprietary Elevai Exosomes™ technology. The study, conducted in partnership with the National Hair Loss Medical Aesthetics (NHLMA), demonstrated potential benefits for individuals experiencing hair loss or thinning.
Key findings include:
- Ceased crown inflammation
- Reversal of miniaturized hairs
- Recovery of dormant hair
The treatment involved scalp microneedling with Elevai empower™ in-office, followed by at-home use of Elevai enfinity™. Elevai is now conducting further research on their new S-Series Root Renewal System™, which combines exosome and mitochondrial technology for enhanced scalp and hair vitality.
Elevai Labs has partnered with Yuva Biosciences to file two innovative patents aimed at enhancing hair and scalp care technology. The first patent addresses the combination of Elevai exosomes and Yuva's Y100 mitochondrial technology, potentially offering superior results. The second patent focuses on the use of lipid bilayer nanoparticles as a delivery system. These developments will be integrated into Elevai's S-Series Root Renewal System™, incorporating PREx™ and Y100 technologies, already endorsed by BosleyMD.
The Y100 technology, developed through Yuva's MitoGPT™ AI platform, is highly regarded for combating age-related hair and scalp issues. Elevai's strategic expansion includes full-scale marketing of the S-Series, anticipating significant interest from hair and scalp care professionals.
Elevai Labs, Inc. (NASDAQ: ELAB) has announced positive results from a clinical study of its Elevai enfinity™ topical exosome serum. The 12-week study, conducted on 29 participants aged 40-70 with mild to moderate facial photoaging and sensitive skin, showed the product to be safe and tolerable with significant improvements in various aspects of skin appearance.
The study, led by renowned dermatologist Dr. Zoe Draelos, assessed the twice-daily use of Elevai enfinity™ on facial firmness, skin tone, wrinkles, and smoothness. CEO Dr. Jordan R. Plews emphasized the importance of this rigorous study in validating the product's effectiveness. Elevai plans to publish the full study results soon and continues to prioritize scientific research as part of its commercial strategy for 2024 and beyond.
Elevai Labs Inc. (NASDAQ: ELAB) announced preliminary positive research data from a study with Dalhousie University, highlighting the potential of its proprietary exosome technology for skin health applications. The study revealed that ELEVAI exosomes™ contain over 800 proteins associated with wound healing, immunomodulation, and skin extracellular matrix remodeling.
Key findings include:
- ELEVAI exosomes™ demonstrated typical exosome morphology and diameter
- They were enriched with proteins related to ECM organization, hemostasis, and cellular stress response
- The protein profile was statistically significant and notably enriched compared to 54 previously published exosome protein datasets
- Proteins found may help prevent skin thinning, loss of elasticity, and wrinkle formation
Elevai plans to conduct further experiments to expand the research scope and explore broader applications such as bone regeneration, wound healing, and immune regulation.
Elevai Labs Inc. (NASDAQ: ELAB) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Revenue increased 91.3% to $605,529 for Q2 2024 and 165.6% to $1,220,092 for H1 2024 year-over-year.
- Gross margin improved to 72.5% for both Q2 and H1 2024.
- Net loss of $1,412,491 for Q2 and $2,809,741 for H1 2024.
- Launched B2B/B2C Elevai Skincare e-commerce platform.
- Established subsidiaries: Elevai Biosciences Inc. and Elevai Skincare Inc.
- Initiated corporate restructuring to reduce annual operating expenses by an estimated $800,000.
- Received research grant from MITACS Canada.
- Formed Scientific Advisory Board for Elevai Biosciences.
The company continues to focus on growth opportunities and increasing shareholder value through strategic acquisitions and investments in biotech, cosmetic, health, and wellness sectors.
Elevai Labs Inc. (NASDAQ: ELAB) has announced the appointment of Orian Shirihai, MD, PhD, to the Scientific Advisory Board of its subsidiary, Elevai Biosciences Inc. Dr. Shirihai, a Professor of Medicine at UCLA and Director of the UCLA Metabolism Research Theme, will support the advancement of EL-22, a first-in-class engineered probiotic approach to address muscle preservation during weight loss treatments.
Dr. Shirihai's expertise in metabolism and obesity research, with over 180 publications and multiple NIH-funded projects, is expected to be valuable in developing EL-22 as a differentiated, oral myostatin approach for obese patients. Elevai Biosciences plans to recruit additional scientific leaders in metabolic health and obesity to join its team.
Elevai Labs Inc. CEO, Graydon Bensler, expressed enthusiasm for the developments at Elevai Biosciences and indicated the company's focus on increasing shareholder value through strategic acquisitions and investments in biotech, cosmetic, health, and wellness spaces.
Elevai Labs (NASDAQ: ELAB) has launched the Elevai S-Series™, a new hair and scalp care product line under its subsidiary Elevai Skincare. Unveiled at The Aesthetic Show in Las Vegas on June 28, 2024, the S-Series utilizes a unique dual mechanism combining exosomes and mitochondrial technology. This three-part system, including the Root Renewal System™, is designed to address issues like thinning hair by promoting scalp and hair vitality. The technology integrates Elevai's proprietary PREx™ and Yuva Bioscience's Y100, identified using AI platform MitoGPT. The S-Series aims to provide a scientifically-backed, cost-effective solution for both men and women.
Elevai Labs, a leader in the medical aesthetics sector, has announced that its subsidiary, Elevai Skincare, will debut a new product line at The Aesthetic Show 2024, held from June 27-30 at the Wynn Las Vegas.
At Booth #511, Elevai will showcase the latest innovations in stem cell exosome products. CEO and Co-Founder Jordan R. Plews, PhD, will introduce the new product line during a presentation on June 28 at 3:30 PM, joined by guest speaker Keshav Singh, PhD, an acclaimed scientist and inventor of one of the key ingredients in the new products.
This event marks a significant step for Elevai in advancing its product offerings within the medical aesthetics field.
Elevai Labs announced the creation of a new Scientific Advisory Board to support its weight loss program, focusing on the development of EL-22, an engineered probiotic solution aimed at addressing obesity by preserving muscle during weight loss treatments. The board includes experts like Dr. Roger A. Fielding, a leading researcher in skeletal muscle function, and Dr. Eduardo Grunvald, an obesity medicine physician. Elevai CEO Dr. Jordan R. Plews emphasized the board's role in advancing Elevai's vision to address the unmet medical needs of obese patients.
Key members include Dr. Fielding, known for his extensive research on muscle mass decline and nutrition, and Dr. Grunvald, who has vast experience in obesity medicine and weight management. Elevai aims to recruit additional experts in metabolic diseases and obesity to its advisory board.
FAQ
What is the current stock price of PMGC Holdings (elab)?
What is the market cap of PMGC Holdings (elab)?
What does Elevai Labs specialize in?
What is the ELEVAI Exosome technology?
How can consumers purchase Elevai products?
What recent achievements has Elevai Labs made?
What is EL-22?
Who is Elevai Biosciences?
What markets does Elevai target with its products?
How does Elevai support its distribution partners?
What is the company's commitment to innovation?
Where can I find more information about Elevai Labs?
